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over other LAIs in terms of discontinuation due to AEs. This study provides support 
for formulary decision-making in the absence of head-to-head data.
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Objectives: In recent years workplace mobbing attracts notice in public and sci-
ence. Victims of workplace mobbing frequently suffer from depressions, somatic 
symptoms, may develop alcoholism or other substance abuse disorders and show 
increased risk of suicidal behavior. The aim of this study was to calculate the 
number of patients with a workspace mobbing documentation and their diagnosis 
profile in general practices in Germany between 2003 and 2012 based on the data 
from a large epidemiological database. MethOds: This retrospective study ana-
lysed longitudinal routine care data collected by general practitioners in Germany 
(IMS® Disease Analyzer). Data from patients with notice as workplace mobbing 
(N= 2653) and without such notice (N= 2653) from 199 general medical practices 
in Germany (Disease Analyzer database; 01/2003 to 12/2012) were matched for 
age (41 ± 13 years), gender (male: 33%), health insurance (private: 5%) and retro-
spectively analyzed. Odds Ratio (OR; Logistic regression) for depression, anxiety, 
somatoform disorder, migraine and sleep disorder (follow-up: 3 years) were calcu-
lated. Results: In 2003, 24 (projected to national level: 2448) patients were docu-
mented as mobbing victims; this number continuously increased to 429 (projected 
to national level: 43758) in 2012. Shares of female patients and mean age have not 
significantly changed from 2003 till 2012. In workspace mobbing persons there 
was a increased risk of depression (OR: 4.11, p< 0.001), anxiety (OR: 2.76, p< 0.001), 
somatoform disorder (OR: 3.51, p< 0.001), migraine (OR: 1.41, p= 0.003) and sleep 
disorder (OR: 2.32, p< 0.001). cOnclusiOns: This retrospective database analysis 
showed that experience of workspace mobbing was associated with increased 
prevalence of psychiatric and neurological problems. Further research is required 
to understand this complex issue.
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Objectives: As the cultural adaptation process of PROs (Patient Reported 
Outcome instruments), every version of PROs should be validated. However, little 
is known whether those validated PROs are identical in terms of the test perfor-
mance (operating characteristics). In this study, we investigated PHQ-9 (Patient 
Health Questionnaire-9 for depression) using the meta-analysis. MethOds: We 
searched PubMed for studies examining diagnostic accuracy of PHQ-9. Then we 
extracted or retrieved 2 x 2 data from each study and meta-analysis was performed 
using Bivariate model (Reitsma et al. 2005). As the language versions of PHQ-9 
and regions where the studies were conducted would be potential confounding 
factors, we performed meta-regression. Bivariate meta-analysis of the subgroup 
(region, language) was explored. Results: Twenty-eight studies met our inclu-
sion criteria. Univariate meta-regression showed that all the covariates assessed 
such as language, region significantly contributed to the heterogeneity of sensi-
tivity (I^2= 82.7) and specificity (I^2= 92.5) among the studies. Meta-analysis of 
subgroup of the regions and languages was made using bivariate model; studies 
conducted in North America (6 studies), Europe (13 studies), or Asia & others 
(9 studies); LogitSe of North America, Europe and Asia& other were 1.66, 1.45, 
and 1.48, respectively. Logit Sp of these regions was 1.87, 1.90 and 2.22, respec-
tively. cOnclusiOns: Results suggest that operational characteristics would 
influenced by the regions, language version of PHQ-9. Therefore, when considering 
a multiregional study using PHQ-9 as screening tool, there would be a chance of 
some imbalance among regions. Therefore, before initiation of the clinical studies, 
efforts need to minimize the heterogeneity of the definite diagnosis, e.g. training 
to the investigators, or central diagnosis.
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Objectives: To investigate factors associated with changes in attention-defi-
cit/hyperactivity disorder (ADHD) symptom severity and quality of life (QoL) in 
patients who were responders and stable on their pharmacotherapy at study 
entry. MethOds: “AUTOR” is a European prospective, observational study inves-
tigating factors associated with ADHD severity changes during a 2-year follow-up 
period in patients aged 6-17 years. At baseline, patients had received the same 
pharmacotherapy for 3-8 months and had a Clinical Global Impression (CGI)-ADHD-
Severity score of mild or lower and a CGI-ADHD-improvement score of improved/
very much improved since treatment initiation. Data were collected at naturally 
occurring visits coinciding with observation windows (postbaseline): 0, 3, 6, 9, 12, 
18, and 24 months, and ±6 weeks. ADHD symptom severity worsening was defined 
as a ≥ 2-point increase from baseline in CGI-ADHD-Severity score. The Child Health 
Profile-Child Edition (CHIP-CE) was used to measure QoL. Multivariate logistic 
regression was used to assess the association of different factors with changes 
in ADHD severity at any time postbaseline. Mixed-model repeated measures 
(MMRM) regression was used to estimate adjusted differences between treatments. 
Propensity scoring was used to adjust for imbalanced covariates before treatment 
comparisons. Results: Data were analyzed from 704 patients (mean [standard 
Objectives: In 2012, ivabradine was centrally approved by the EMA for Chronic 
Heart Failure treatment. Through ivabradine NICE and HAS decisions analysis, the 
objective of this policy research is to illustrate the divergence of HTA decisions 
despite a consistent efficacy, effectiveness and economics information. MethOds: 
NICE and HAS reports were fully reviewed with a focus on decisions outcomes. 
Then, convergences and divergences between HAS and NICE decisions were high-
lighted. Results: NICE recommended for use ivabradine for patient with NYHA 
class II to IV with systolic dysfunction, with sinus rhythm with a heart rate ≥ 75 
bpm, in combination with standard therapy or when beta-blocker therapy is con-
traindicated or not tolerated, and with a left ventricular ejection fraction ≤ 35%. 
Decision made by NICE was mainly based on results of one subgroup defined post 
hoc on the request of EMA. HAS rated the actual benefit of ivabradine as impor-
tant for the labelled indication, nevertheless HAS distinguishes 2 subpopulations: 
one with minor improvement of actual benefit - patient with NYHA class II to III 
with systolic dysfunction in sinus rhythm with the heart rate ≥ 77 bpm and in 
which beta-blockers are contraindicated or not tolerated- for the other patients, 
HAS stated that ivabradine does not provide improvement in actual benefit. HAS 
based its decision mainly on the results of one subgroup defined a priori in which 
ivabradine was superior to each individual components of the primary combined 
endpoint. cOnclusiOns: While EUnetHTA attempts to provide a coordinated opin-
ion on comparative effectiveness, HTA decisions continue to be divergent across 
Europe. Ivabradine NICE and HAS decisions divergences exemplify once more the 
inconsistency of HTA decisions and highlight the obstacle for the establishment 
of a jointed EUHTA body.
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Objectives: The primary objective of this study was to report the clinical out-
comes, i.e. routine calculation of time in therapeutic range (TTR), bleed events and 
thromboembolic events for patients on warfarin in a general practice following 
the introduction of quality improvement initiatives. A secondary objective was 
to estimate the cost of care of these patients managed from the perspective of 
the general practice. MethOds: Clinical data were analysed annually using a 
General Practice database, adapted to allow calculation of TTR for all patients pre-
scribed warfarin for the years 2009 (baseline), to 2011 (Year 2). Decision trees were 
constructed to reflect typical episodes of care for patients with atrial fibrillation 
(AF). Resource use and unit cost data were applied to each node in the decision 
tree. The probabilities of events occurring were derived from the literature and 
expert clinical opinion. A 60% TTR was used as a reference criterion for patient 
outcomes. Ethical approval for the study was obtained. Analysis was performed 
in SPSS®. Results: The TTR at baseline was 54%, rising to 61% in Year 1 and 63% 
in Year 2. One patient suffered a haemorrhagic stroke in the baseline year (TTR 
71%), and in the same year there were 4 thromboembolic events. No major haem-
orrhagic or thromboembolic events have been recorded in the follow-up years. 
The median cost per patient with AF was € 276 (using a median of 12 INR tests per 
annum). cOnclusiOns: The introduction of routine assessment of TTR in the 
practice has resulted in a significant improvement in care as demonstrated by the 
rise in TTR values, and adherence to international best-practice criteria. Clinically 
significant outcomes on patient care are also evident with the absence of major 
bleed events or thromboembolic breakthrough events. The study highlights the 
feasibility and benefits of enhanced care at local level.
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Objectives: Treatment with antipsychotic medication is an important element of 
relapse prevention in the management of schizophrenia. However, approximately 
50% of patients with schizophrenia miss taking > 30% of their medication, there-
fore the use of long-acting injectable (LAI) formulations is an important option for 
patients partially or non-adherent to oral formulations. This study aimed to com-
pare LAIs in terms of efficacy and safety. MethOds: A systematic literature review 
in PubMed, EMBASE, Cochrane, PsychINFO and conference abstracts was conducted 
to identify relevant randomized controlled trials of LAIs in maintenance treatment 
in schizophrenia. Selection criteria included long-term follow-up, stable patients 
and minimamilly one LAI treatment arm. The primary efficacy outcome was relapse 
rate; rate of discontinuation due to treatment-related adverse events (AEs) was also 
considered in this analysis. Data on discontinuation parameters were analyzed by 
applying a MTC competing risks model appropriate for multinomial distribution 
of data using WinBUGS. Results: Six trials (study follow-up from 24 to 53 weeks) 
were identified, allowing comparisons of aripiprazole (oral and LAI), risperidone 
LAI, paliperidone LAI, olanzapine (oral and LAI), haloperidol LAI and placebo. The 
total patient number was 3402, of which 534 (16%) received aripiprazole. Compared 
to placebo the risk of relapse was the smallest for aripiprazole LAI (mean hazard 
ratio [HR]= 0.26, 95% confidence interval [CI] 0.12-0.50) and risperidone LAI (HR= 0.29, 
95% 0.05-0.83). The risk of discontinuation due to AEs was lower than placebo for 
aripiprazole LAI (HR= 0.72) and higher than placebo for the other LAIs (paliperidone 
LAI: HR= 5.08, risperidone LAI: HR= 12.06, olanzapine LAI: HR= 6.58, haloperidol LAI: 
HR= 4.19). cOnclusiOns: The MTC suggests that aripiprazole LAI is at least as effi-
cacious in the management of relapse prevention as other LAIs with an advantage 
